BNTH has many first-class production teams engaged in the television industry. In terms of business model innovation, BNTH and China Central Television (CCTV) have a new business model of "joint production and joint operation". In terms of program content, BNTH takes investment, creation and dissemination of theme works as its guiding ideology. In terms of communication, BNTH takes "Poverty Alleviation IP" as its corporate goal, and is committed to becoming a national model of targeted poverty alleviation.

At present, BNTH is mainly responsible for the production and dissemination of CCTV's poverty alleviation programs. It promotes the nationwide poverty alleviation work through the interaction of Large-N-Small Screens*, and call on all social forces to participate in the poverty alleviation work. In recent years, BNTH has undertaken the shooting and production of Never Leave Behind, a grand TV poverty alleviation program of CCTV, and has gained good reputation.

After years of development, BNTH has maintained close strong cooperation with more than 200 domestic media, including CCTV, many satellites TV channels and network video medias, and more than 3000 scholars, experts and film and television workers from all walks of life engaged in poverty alleviation. BNTH has carried out extensive and in-depth cooperation with Alibaba, Tencent, Weibo, Jingdong, Beijing Gas, RRL, etc.

The underlying assets are the assets related to animal health business owned by Xinbeijiang Pharmaceutical on the base date, including but not limited to mechanical equipment, electronic equipment and other fixed assets, as well as intangible assets, approvals, qualifications, etc.

On the date of this announcement, Lijian (Guangdong) Animal Health Co., Ltd. is a joint venture of the company, which is 51% and 49% owned by the company and Jiankangyuan (600380) respectively.

Considering the characteristics and good development prospects of the business related to animal health products, the company and Jiankangyuan have integrated their advantageous resources and jointly invested in the establishment of a joint venture (independent business operating company). New Beijiang Pharmaceutical will divest the assets related to the operation of animal health business into the joint venture. On the one hand, it can enable New Beijiang Pharmaceutical to focus more on the core business of raw materials (including pet raw materials) and intermediates, On the other hand, from the perspective of the company's overall interests, it is also conducive to strengthening the independence of different businesses and the degree of operation specialization, and further accelerating the business layout and promotion in the field of animal health care, which is conducive to consolidating and improving the company's advantages in the field of animal health raw materials and comprehensive business competitiveness, and entering the rapidly developing consumer market of animal health preparations, in line with the strategic requirements of the company's innovative development, It is of great significance to the future development of the company.

The firm is led by seasoned investment management professionals who have held senior-level positions at some of the world’s largest investment firms and have decades of international experience, including the Greater China region, in all aspects of capital markets. Since its inception, Cedrus’ mission has been becoming the leading investment service solution provider, offering knowledgeable investors objective advice, creative global solutions, aligned incentives and transparency.

Since its establishment, ATMS Health has successfully helped many medical institutions audit and analyze their surgical instrument assets, to improve their budgeting, standardization and prediction capabilities of surgical packages, by providing and installing cutting-edge asset management software such as audit, readiness and gap analysis for MDRD workflow and procedures and recommendations, helping them to meet with norms and standards.

In addition, ATMS Health is also involved in the production, manufacturing and marketing of medical linens, as well as providing a complete traceability management solution for the reprocessing cycle of those medical linens by implementing RFID and other high-end technologies.

Other products:

Chronolnventory: is a software of management of medical devices asset & inventory.

ChronoSteril & ChronoScopy: are tracking and management System of MD and flexible scopes in MDRD.

Marking services: for individual MD contains dot-peen marking technology and fiber-laser marking technology.

In addition, several prescription drugs are manufactured and distributed, including under license from Merck & Co. and Novartis. Contract manufacturing on behalf of other manufacturers is another mainstay of ROVI.

For the Moderna vaccine mRNA-1273, which is partly manufactured in a Lonza plant in Switzerland, the packaging, filling and delivery takes place in Pozuelo de Alarcón.

ROVI’s main products contains the following as: Sodium Bemiparin Injection, Enoxaparin Sodium Injection, Injectable Risperidone, Indacaterol Maleate and Glycopyrronium Bromide, Sacubitril and Valsartan, Ezetimibe and Atorvastatin etc.

Since 2019, ROVI has been part of the Spanish small cap index IBEX Small Cap.

BGI Co-Win (Shenzhen) Private Equity Co., Ltd. (BGI Co-Win) established in January 2016, is a private equity fund management organization co-founded by Hi-Nice Shine investment team and well-known professional investment teams in the field of life and health such as CAC Capital, Qianhai Huxiao Capital, etc., and Beijing Genomics Institution (well known as BGI Group), one of the world’s leading gene technology companies.

BGI Co-Win focuses on companies with high potential in the life science industry, builds a market-oriented ecological investment platform for life and health industry, and achieve resource sharing and co-win development of industrial resources providers, fund investors and invested companies.

The partner team of BGI Co-Win has more than 20 years of investment and project incubation experience, has fully experienced the fund cycles of fund raising, investment, fund management and fund exit, and has established a mature investment management system.

Under the professional concept of "R&D Driven Investment", BGI Co-Win adheres to the method of "Draw industrial distribution map and actively invest according to the map", and especially focuses on enterprises that master core technologies or platform enterprises specializing in gene technology, digital medicine, biomedicine etc. The fund mainly aims on projects in the initial stage and early stage of growth, supplemented by projects in the middle and late stages of growth, so as to achieve reasonable allocation in the project investment stage.

BGI Co-Win relies on the resources of partners such as BGI Group and its past successful investment partners in life sciences, to provide industry development coordination, and provide legal, financial, human resources and other services for the invested projects, so as to help the invested projects improve their operation and management capabilities and achieve stable and sustainable development.

At present, BGI Co-Win’s investments ranges from treatment, diagnosis, prevention to health management, from new technology and new platform of IVD, new application scenarios of NGS, to key components of the industrial supply chain; from Cellomics to nucleic acid drugs, polypeptide drugs, cell/gene therapy, synthesis and other fields, with constantly creating value for customers and achieving mutual benefit and co-win results.

Since 2013, China has launched a new round of state-owned enterprise reform characterized by mixed ownership of state-owned company and private company. In 2014, Hi-Nice Shine actively participated in the reform of mixed ownership of state-owned enterprises, and successfully took the controlling stake of Sinopharm Nutraceutical. Hi-Nice Shine took advantage of its industry resources to build influence, transformed Sinopharm Nutraceutical, and constantly committed to innovation incubation and equity investment in the pharmaceutical industry.

After years of hard work, the investment of Sinopharm Nutraceutical covers new drug research and development, medical device innovation, insurance, prescription transfer, cross-border related services, and other fields.

SOIMI is the first specialized institute in China that integrates services of creative ideas collection, prototype development, patent protection, proof of concept (PoC), technology transfer, product registration, and technology promotion. It has more than 30 senior professionals in the industry, including clinical engineers, patent lawyers, technical managers, regulatory registrars, quality system specialists, etc.

SOIMI has good resources in clinical, technical and industrial. At present, it has gathered more than 100 in-depth partners, including well-known universities, high-level hospitals, cutting-edge scientific research institutes and innovative enterprises, and built an international technology transfer cooperation network covering USA, UK, Japan, France, South Korea, Canada, Sweden and other countries.

SOIMI focuses on providing full link comprehensive services in the medical field of "Creative Patenting, Patent Productization, and Product Industrialization", closely focusing on clinical needs and demands. Its business covers clinical innovation evaluation, patent layout protection, product designing and development, prototype production, product registration application, business model designing, academic resource connection, joint research of industry, university, and research, technology transferring and project incubation, industrial capital connection and other medical innovation and entrepreneurship areas.

At present, the Institute has served more than 50 medical device innovation projects originating from clinics. The project covers medical devices of Class II active, passive, Class III passive and implants, and in vitro tumor diagnostic products, involving multiple departments such as urology, general surgery, digestion, anesthesia, radiology, intracardiac, interventional, etc.

Founded in 2018, Kousai has R&D centers in the cities of both Shanghai and Zhongshan. It is a high-tech entitled enterprise focusing on the field of tumor immunotherapy, and is committed to the research, development and industrialization of personalized Dendritic Cells (DC) tumor therapy vaccine (DC vaccine).

Together with the Cancer Hospital affiliated to Tokyo Medical and Dental University, Wuhan University and Fudan University, Kousai has built a high-quality DC technology platform named Eco-DCVax, aiming to develop internationally leading, domestically initiated, inclusive, safe and convenient DC vaccine products with independent intellectual property rights, and thus become a leading and world-class DC vaccine company in China.

Kousai was jointly founded and led by senior industry experts and industrialization team, integrating production, learning and research. The founder and CEO, Dr. Liu Huining, is a doctor of immunology from Tokyo Medical and Dental University in Japan, an MBA from Tulane University in the United States, and a post-doctoral from Harvard Medical School in the United States.

She has rich experience in scientific research and drug development and once worked in BMS, IQVIA and other well-known enterprises, led and participated in more than 50 clinical trials and more than 10 new drug applications, and led several drugs to be listed in many countries around the world.

The DC vaccine developed by Kousai focuses on the disease field where there is no effective treatment method at the moment. It has laid out the related diseases caused by EBV, including lymphoma, post transplant lymphoproliferative disease (PTLD), chronic active EBV infection, nasopharyngeal carcinoma (NPC), gastric cancer, multiple sclerosis and other indications. At the same time, it actively carries out the expansion of multiple disease fields, such as cervical carcinoma, hepatitis, glioma, breast cancer, renal carcinoma, leukemia, AIDS, pancreatic cancer, and so on.

At present, the company has reached cooperation intention with many research institutions to comprehensively promote the application of clinical trials, including exploratory clinical research (IIT) of individualized DC vaccine for various types of tumors, and evaluate the clinical effect of DC vaccine.

In the first half of 2022, Kousai announced a round of Pre-A financing of tens of millions of yuan.

Global Health (Tianjin) Intelligent Manufacture Co., Ltd. (Global Health Manufacture) was established in 2019 and is located in Jimei Industrial Park, Xiqing Economic and Technological Development Zone, Tianjin, is an intelligent hardware solution service provider integrating R&D, manufacturing and sales, focusing on the diversified combination and customized application of intelligent products and management systems in medical scenarios. The company adheres to innovation as the core, applies different types of technology, and combines the actual demands from scenes to provide intelligent hardware equipment and management systems for end customers, to open up medical application scenarios, and create sustainable value for all roles in the supply chain.

With RFID, weighing and image recognition as the underlying technical supports, the intelligent hardware solution for medical materials uses AI, big data, cloud computing and the Internet of Things to independently develop a variety of medical intelligent hardware devices, such as RFID cabinets, weighing cabinets, refrigerated cabinets, cabinets for psychotropic and anesthetic, intelligent shelves, intelligent cart, intelligent medicine boxes, etc., which can be directly applied to hospital clinical and medical health scenes to achieve fine management of medical materials in all aspects, reduce hospital management costs, improve the efficiency of medical staff, and provide one-stop solutions for hardware lean management of hospitals.

Intelligent hardware solution of Global Health Manufacture optimizes the medical material management process and reduces the material management time of nursing staff; reduce the risk of material loss and loss rate, improve the accuracy of cost accounting, and achieve “zero inventory” of department in financial aspect. At the same time, the whole process monitoring is used to achieve the intelligent, standardized and safe management of hospital materials on the basis of meeting the requirements of saving patients' lives.

Empower medical with technology, escort health with intelligence, and entrench life with responsibility!

Through years of strategic cooperation with the hospital, Global Health Medical has accumulated rich experience in the group procurement and distribution of medical consumables, established a complete supply chain management system, formed a detailed product database, complete business departments and professional staffing, established a strong logistics system and various expert resources that can be deployed in a timely manner. In order to adapt to the rapid development of China's medical industry, Global Health Medical introduced strategic investor, Hi-Nice Shine Pharmaceutical Ltd., to share medical resources in 2008.

At present, Global Health Medical has more than 60 technical teams with professional experience in clinical, nursing, inspection, information, logistics, etc., more than 10 R&D and design teams, and more than 260 operation and maintenance service teams. In terms of technological innovation, the company has successively obtained more than 40 patents and software copyrights related to medical device consumables.

At present, Global Health Medical 's business covers hundreds of various types of hospital including public hospitals, private hospitals and military hospitals in the provinces and cities of Henan, Guangdong, Guangxi, Liaoning, Sichuan, Beijing, Shandong, Shenzhen, Anhui, Jiangxi and so on.

By 2021, through continuous efforts, the number of cooperative manufacturers and suppliers of Global Health Medical has grown from the initial 130 to more than 2,000; The specifications of purchased and distributed products have increased from the initial 1,100 to more than 35,000, and the annual procurement amount is nearly 600 million yuan.

As an intelligent supply chain service provider of medical materials with a technical and management team of nearly 300 people, Global Health has obtained more than 50 invention patents, software copyrights, and has been entitled various qualifications and social honorary certificates. With an independent software development center and hardware production base, Global Health has the ability to independently develop its software and produce the hardware.

Global Health takes lean management as the leading ideology, combines its own funds, personnel and technology as the resource support, makes use of AI technology, Big Data, cloud computing, the Internet of Things and other modern technical means, optimizes the medical materials management process, collaborates the advantages of all parties, reforms the supply chain system, and jointly creates a highly applicable medical materials management model with the hospital in the actual scene of the hospital, achieves the whole process closed-loop management and life-cycle traceability of medical materials, thus makes unremitting efforts to reduce cost and burden, improve quality and efficiency of hospital materials management.

Relying on the main product support systems such as the intelligent supply chain management system (SPD system), the intelligent supply chain application cloud platform system, the intelligent supervision system, the intelligent hardware equipment, the professional services of the in-situ team, and other major product support systems, Global Health cooperates and collaborates with manufacturers and suppliers, logistic management departments, clinical departments, finance department, medical insurance and supervision departments (from government) and other supply chain roles and links.

As a result, Global Health creates a package solution covering the whole process of closed-loop management of medical materials, including out-hospital procurement acceptance, in-hospital warehousing, in-hospital smart logistics, clinical consumption settlement, data intelligent analysis, automatic replenishment and early warning regulatory etc., and then achieves data security, process standardization, operation standardization, business collaboration and management visualization.

Through close cooperation with medical institutions, Global Health has changed from a simple product delivery model to a deep development integration model, and from a single channel output to multi-channel interaction. With combination of the advantages of enterprise and the demands and scenarios of hospital, under the multi-dimensional supervision, Global Health works together with all parties in the medical material supply chain for the goal of creating a new model of hospital material management system.

Global Health is continually committed to achieving the goal of reducing costs of management, improving work efficiency and capital utilization efficiency, elevating operation efficiency and supervision efficiency, and enhancing social and economic benefits for medical institutions. It is deeply integrated into the modern hospital management system to help the high-quality development of healthcare system.

The main products of KNRT include: Performance Management Service System for Primary Medical Institutions, Chronic Disease Management Service System, Intelligent Pharmacy and Prescription Service System, Cloud Pharmacy and Prescription Service, and Intelligent Supervision Service Platform.

◆Performance Management Service System for Primary Medical Institutions:

The operation mechanism and mode of primary medical institutions across the country are facing profound changes, and the implementation of digital application scenarios is more urgent. KNRT closely cooperates with local Health Commission and medical institutions and makes full research. Based on standard workload, Big Data, AI and other appropriate theoretical technologies, it has built a set of efficient, scientific and suitable digital support and supervision platform for primary medical institutions on the basis of innovative management mode change, comprehensively promoting the modern development of governance capacity of primary medical institutions.

◆Chronic Disease Management Service System:

Using artificial intelligence chronic disease management tools, we will provide patient side services based on community medical care, fully link high-quality resources of all parties around common chronic diseases such as Hypertension, Diabetes, Coronary disease, Stroke, Chronic obstructive pulmonary disease (COPD), Chronic renal failure (CRF), and provide long-term, scientific, and intelligent basic health services for community residents. In combination with the deep application and integration of new technologies at the primary level, KNRT provides primary medical institutions with flying wings on digitalization, which is in line with the medium - and long-term strategy of national chronic disease prevention and control. In order to better meet the health demands of residents at primary level and achieve the ultimate goal of "Healthy China 2030" as soon as possible, KNRT has made its continuous efforts.

◆Intelligent Pharmacy and Prescription Service System:

Based on the powerful drug library and millions of prescriptions and medication safety rules, combined with Big Data analysis, KNRT reduces the work intensity for pharmacists on the premise of ensuring medication safety. At the same time, it can also improve the diagnosis and treatment ability of doctors, and improve the efficiency of drug supervision of managers.

◆Cloud Pharmacy and Prescription Service:

Combining with the concept of "Internet plus", the core data library and technical advantages of the pharmaceutical care system that have been dedicated for many years, KNRT conducts online review of doctors' prescriptions and medication. It is applicable to the new mode of prescription review in the scenes of Internet Hospitals and online pharmacies.

◆Intelligent Supervision Service Platform:

On the basis of the national policies of promoting hierarchical diagnosis and treatment, strengthening the supervision of medical institutions' diagnosis and treatment behavior, standardizing doctors' diagnosis and treatment behavior, and reducing patients' medication safety risks etc., KNRT provides powerful and reliable management support services for National Health Commission, medical institutions and doctors, to achieve regional data sharing and meet the needs of government supervision and decision-making.

The company mainly deals in domestic cardiovascular, cerebrovascular, nervous system and immune system drugs, and introduces first-line drugs from international markets of major disease. The company always adheres to the quality policy of "Quality first, Legal operation, Customer first" and the management philosophy of "Service first, Mechanism innovation". The company team, with the attitude of focus, quality and integrity, promotes the common growth of the enterprise, and strives to create a new mode of drug distribution enterprise with market orientation and customer demand as the core.

Licensed drugs: Bemiparin Sodium Injection, Enoxaparin Sodium Injection, Injectable Long-acting Risperidone Lipid Microspheres, Irsogladine Maleate Tablets, etc.

Cooperative enterprises: large international pharmaceutical enterprises such as Laboratorios Farmacéuticos ROVI, S.A. and Nippon Shinyaku Co., Ltd.

*If there is any suspected adverse event, medical problems or product complaints, please call the hotline to give us feedback*

Bemiparin Sodium Injection:

Heparin is a mixture of sulfated polysaccharides from animal sources (pigs or cattle). Because of their good antithrombotic properties, they have been widely used, such as preparing antithrombotic drugs, drugs for treating cardiovascular diseases, and drugs for treating cerebrovascular diseases. Although heparin has achieved good results in clinical application, it has also brought many adverse reactions, such as bleeding, thrombocytopenia caused by heparin, allergic reactions, etc. These adverse reactions make doctors have some scruples in the use of heparin.

However, the low molecular weight heparin prepared by pyrolysis of unfraction heparin has the advantages of good injection absorption, long half-life period, high bioavailability, less bleeding negative effects, and no need for laboratory monitoring. At present, low molecular weight heparin is available on the market with Nadroparin Calcium, Enoxaparin Sodium, Dalteparin Sodium, and Bemiparin Sodium, among which Bemiparin Sodium is called the second-generation of low molecular weight heparin because of its high efficiency and low toxicity. Compared with other low molecular weight heparin, Bemiparin Sodium has more advantages such as better antithrombotic ability and better pharmacological properties (refers to the figure below).

Bemiparin Sodium is the first second-generation low molecular weight heparin in the world, with an average molecular weight (AMW) of 3600 Da. It was successfully developed by a Spanish company called Laboratorios Farmacéuticos ROVI, S.A. in 1998, and has covered more than 60 countries and regions in the world since its launch. At present, the general agent for China is Tianjin Pacific Hongye Pharmaceutical Development Co., Ltd.

Bemiparin Sodium is mainly used to prevent venous thrombosis, treat deep venous thrombosis and anticoagulation for extracorporeal circulation devices. It is a prescription drug and can be used in orthopedics, general surgery, hemodialysis, recurrent abortion and other fields.

Bemiparin Sodium has been clinically proven to significantly reduce the incidence of VTE (venous thromboembolism) in cancer patients undergoing abdominal and pelvic surgery, and there is no significant risk of bleeding. The usage and dosage of the first dose in 6-hour after operation are in line with the clinical medication experience, providing a more optimized choice for Chinese patients to prevent VTE after operation.

*If there is any suspected adverse event, medical problems or product complaints, please call the hotline to give us feedback*

The predecessor of the factory is a workshop of functional food of a large pharmaceutical enterprise, with nearly 20 years of experience in high-tech R&D, production and manufacturing. The company has a number of modern food production lines, and has independent R&D, production and testing capabilities of various products, and has obtained the HACCP accreditation of Food Safety Management System.

At present, the company has formed a multi product matrix covering functional food, solid drinks, tea drinks and other subdivided fields, and has successively launched capsules and tablets of Pycnogenol and other health products. Also, new products, Coenzyme Q10 capsules and Melatonin capsules (brand name: Yihengyuan), have been launched recently.

The company has successively launched more than 60 varieties of five major dosage forms represented by the classic cough medicines "Qinbaohong cough relieving products" (QBH). The main varieties of the company are all national protected varieties of traditional Chinese medicine, which are exclusively produced nationwide. The series of products are highly trusted by patients with their efficient, rapid and safe curative effects, and the cumulative sales have reached 2 billion yuan.

Now Jinbeiyao covers an area of nearly 50,000 square meters, with a building area of nearly 20,000 square meters, an annual production capacity of more than 600 million tablets and more than 500 tons of oral liquid. "Pursue gold quality and build classic Beiyao" is the belief of Jinbeiyao. It continues to focus on drug research and development and production, and strives to improve human health and quality of life!

Since its establishment, the company has been adhering to the business philosophy of "quality first, reputation first" and committed to becoming a professional chronic disease drug manufacturer in China. Over the years, the qualified rate of market sampling has reached 100%, which has a good reputation in the industry. It has been honored by the Tianjin Administration for Market Regulation as "A-level enterprise for quantitative grade and classified management of drug production", "reassuring pharmaceutical manufacturer" and other titles. Since its development, the company has mainly produced APIs, tablets, capsules, granules and other dosage forms.

Main products: Telmisartan, Iron Dextra, Irbesartan Hydrochlorothiazide, Gliclazide Modified, Simvastatin and other varieties.

CRO: Provide registration services for international large pharmaceutical groups and multinational companies in China.

Product registration: provide services such as registration and certification of domestic and foreign pharmaceutical products at National Medical Products Administration (NMPA).

Consulting services: consulting services before product listing and R&D, entrusted processing services after listing, and subcontracting services for overseas products.

BNTH has many first-class production teams engaged in the television industry. In terms of business model innovation, BNTH and China Central Television (CCTV) have a new business model of "joint production and joint operation". In terms of program content, BNTH takes investment, creation and dissemination of theme works as its guiding ideology. In terms of communication, BNTH takes "Poverty Alleviation IP" as its corporate goal, and is committed to becoming a national model of targeted poverty alleviation.

At present, BNTH is mainly responsible for the production and dissemination of CCTV's poverty alleviation programs. It promotes the nationwide poverty alleviation work through the interaction of Large-N-Small Screens*, and call on all social forces to participate in the poverty alleviation work. In recent years, BNTH has undertaken the shooting and production of Never Leave Behind, a grand TV poverty alleviation program of CCTV, and has gained good reputation.

After years of development, BNTH has maintained close strong cooperation with more than 200 domestic media, including CCTV, many satellites TV channels and network video medias, and more than 3000 scholars, experts and film and television workers from all walks of life engaged in poverty alleviation. BNTH has carried out extensive and in-depth cooperation with Alibaba, Tencent, Weibo, Jingdong, Beijing Gas, RRL, etc.

* Large-N-Small Screens: is a new type of show/program interaction, the large screen is the screen on TV of the show/program itself, and the small screen is the screen of mobile phone of livestream of the show/program. When the show/program is under recording, it is firstly available on the network, so that the show/program can receive more attention and clout from fans and viewers on the network before it officially available on TV stream.